Investments, Funding & Disinvestment

Biogen now holds worldwide rights to the investigational therapy, felzartamab, which is currently undergoing Phase 3 clinical trials for several immune-mediated diseases.

AI Diagnostics developed its Ostium digital stethoscope and AI.TB software to support frontline healthcare providers, including nurses, pharmacists, and community health workers.

The therapy, known as NRTX-1001, uses pluripotent stem cells engineered to regulate brain activity and repair damaged neural networks.

Under the agreement, Stereotaxis will pay USD20 million upfront, with up to an additional USD25 million tied to milestone-based payments.

The company grew revenue by 10% to EUR 1.75 billion (USD1.91 billion) while substantially improving profitability and cash generation.

For Daiichi Sankyo, divesting this business allows the company to concentrate resources on its innovative medicines division, where it has emerged as a leader in antibody-drug conjugate (ADC) technology.

The platform offers a comprehensive suite of tools, including a library of AI models, advanced analytics packages, and an AI-powered agent that assists researchers in designing experiments.

CrossBridge Bio plans to submit an Investigational New Drug (IND) application for CBB-120, positioning the candidate for clinical development.

The collaboration leverages JW Pharmaceutical’s established research and development capabilities to accelerate the drug’s entry into South Korea’s growing metabolic disease sector.

Through this agreement, Gilead now controls global rights to KT-200, an oral CDK2 molecular glue degrader designed to treat cancer.